Waystar Weighs Sale Amidst Software Sector Challenges

Waystar, a prominent player in the healthcare software industry, is exploring strategic alternatives including a potential sale, according to seven sources familiar with the situation. The company, which went public in New York two years ago, has enlisted investment bank Evercore to guide the process. This development comes as Waystar's market valuation has plummeted to approximately $4.8 billion following a 24% decline in its share price this year, reflecting a broader downturn in the software sector.

Market Dynamics and Investor Sentiment

Initially, Waystar positioned itself as a technology firm focused on automating administrative tasks for hospitals and doctors, rather than as a traditional healthcare services provider. This strategy aimed to capitalize on the higher valuations generally attributed to tech companies. The company's shares, which debuted at $20, surged to a high of $45 in 2025. However, recent concerns about potential disruptions from advancements in artificial intelligence have exerted pressure on the stock, as noted in a Morgan Stanley report from July.

Background and Ownership Structure

Formed in 2017 through the merger of Zirmed and Navicure, Waystar was taken public in 2024 by its major stakeholders, including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company holding 8%, as reported by LSEG data.

Amid the fluctuating market conditions, the potential sale of Waystar could test investor interest in software businesses. While the plans are in preliminary stages and may not culminate in a sale, the exploration indicates a strategic reassessment by Waystar’s stakeholders.

Responses and Market Reactions

When approached, Waystar declined to comment on the matter. Similarly, Evercore and CPPIB did not provide immediate responses, while EQT and BlackRock also refrained from commenting. The situation highlights the challenges faced by healthcare software providers in maintaining investor confidence amidst technological shifts and market volatility.

The outcome of Waystar's strategic review remains uncertain, but it underscores the ongoing adjustments within the software industry as companies navigate evolving technological landscapes and investor expectations.